Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP), in Healthy Male Subjects With High Density Lipoprotein Cholesterol (HDLc) Blood Concentrations Equal or Below 60 mg/dl.
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2012
At a glance
- Drugs Atherosclerosis vaccine (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Pharmacodynamics
- 12 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.